MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3203-3217

  Passadouro, Marta ^a,b   Pedroso de Lima, Maria C ^a,b   Faneca, Henrique ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Albumin associated lipoplexes; Anti microRNAs oligonucleotides; Delivery nanosystems; Pancreatic cancer gene therapy

Indexed keywords

ALBUMIN; DOCETAXEL; DRUG CARRIER; GEMCITABINE; HUMAN SERUM ALBUMIN 1 PALMITOYL 2 OLEOYL SN GLYCERO 3 ETHYLPHOSPHOCHOLINE CHOLESTEROL; MICRORNA; MICRORNA 10B; MICRORNA 21; MICRORNA 221; MICRORNA 222; OLIGONUCLEOTIDE; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; INDOLE DERIVATIVE; PHOSPHATIDYLCHOLINE; PYRROLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC REGULATION; PANCREAS ADENOCARCINOMA; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; INDOLES; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; PHOSPHATIDYLCHOLINES; PYRROLES; TRANSFECTION;

EID: 84903878322     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S64456     Document Type: Article

References (60)

1. Saif MW. Pancreatic neoplasm in 2011: an update. JOP. 2011; 12(4): 316-321.
2. Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2012; 18(16): 4249-4256.
3. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10-29.
4. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep. 2010; 23(5): 1183-1192.
5. Mardin WA, Mees ST. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol. 2009; 16(11): 3183-3189.
6. Zhang Y, Li M, Wang H, et al. Profiling of 95microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009; 33(4): 698-709.
7. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007; 26(30): 4442-4452.
8. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7): 2257-2261.
9. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17): 1901-1908.
10. Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM. MicroRNA-21modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res. 2011; 42(4): 281-290.
11. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133(2): 647-658.
12. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010; 70(11): 4528-4538.
13. Han M, Liu M, Wang Y, et al. Antagonism of miR-21reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2inactivation by targeting PTEN. PLoS One. 2012; 7(6): e39520.
14. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008; 8(4): 253-267.
15. Vervoorts J, Lüscher B. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci. 2008; 65(20): 3255-3264.
16. Nakayama I, Shibazaki M, Yashima-Abo A, et al. Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells. Int J Oncol. 2013; 43(1): 63-71.
17. Nakata K, Ohuchida K, Mizumoto K, et al. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011; 150(5): 916-922.
18. Lai D, Visser-Grieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep. 2012; 32(4): 361-374.
19. Pedroso de Lima MC, Neves S, Filipe A, Düzgüneş N, Simões S. Cationic liposomes for gene delivery: from biophysics to biological applications. Curr Med Chem. 2003; 10(14): 1221-1231.
20. Simões S, Fonseca C, Faneca H, Düzgünes N, Pedroso de Lima MC. Protein-associated lipoplexes: novel strategies to enhance gene delivery mediated by lipid-based particles, S.T.P. Pharma Sci. 2002; 12(1): 339-344.
21. Hattori Y, Nakamura T, Ohno H, Fujii N, Maitani Y. siRNA delivery into tumor cells by lipid-based nanoparticles composed of hydroxyethylated cholesteryl triamine. Int J Pharm. 2013; 443(1-2): 221-229.
22. Yu B, Hsu SH, Zhou C, et al. Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials. 2012; 33(25): 5924-5934.
23. Simões S, Filipe A, Faneca H, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2005; 2(2): 237-254.
24. Pedroso de Lima MC, Simões S, Pires P, Faneca H, Düzgüneş N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev. 2001; 47(2-3): 277-294.
25. Simões S, Slepushkin V, Pires P, Gaspar R, Pedroso de Lima MC, Düzgüneş N. Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim Biophys Acta. 2000; 1463(2): 459-469.
26. Faneca H, Simões S, Pedroso de Lima MC. Association of albumin or protamine to lipoplexes: enhancement of transfection and resistance to serum. J Gene Med. 2004; 6(6): 681-692.
27. Faneca H, Faustino A, Pedroso de Lima MC. Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes. J Control Release. 2008; 126(2): 175-184.
28. Faneca H, Cabrita AS, Simões S, Pedroso de Lima MC. Evaluation of the antitumoral effect mediated by IL-12and HSV-tk genes when delivered by a novel lipid-based system. Biochim Biophys Acta. 2007; 1768(5): 1093-1102.
29. Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011; 99(2): 108-113.
30. Raymond E, Hammel P, Dreyer C, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 2012; 7(2): 117-125.
31. European Medicines Agency. Assessment Report for Sutent (sunitinib). Procedure No EMA/H/C/000687/II/0021. London: European Medicines Agency; 2010. Available from: http: //www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000687/WC500100433.pdf. Accessed June 26, 2014.
32. Raymond E, Faivre S, Hammel P, Ruszniewski P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol. 2009; 4(4): 253-254.
33. O'Reilly EM, Niedzwiecki D, Hall M, et al; Cancer and Leukemia Group B. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12): 1310-1319.
34. Lu J, Tsourkas A. Quantification of miRNA Abundance in Single Cells Using Locked Nucleic Acid-FISH and Enzyme-Labeled Fluorescence. In: Shah K, editor. Molecular Imaging. New York, NY: Springer; 2011: 77-88.
35. Konopka K, Pretzer E, Felgner PL, Düzgüneş N. Human immunodeficiency virus type-1(HIV-1) infection increases the sensitivity of macrophages and THP-1cells to cytotoxicity by cationic liposomes. Biochim Biophys Acta. 1996; 1312(3): 186-196.
36. Balazs DA, Godbey W. Liposomes for use in gene delivery. J Drug Deliv. 2011; 2011: 326497.
37. Faneca H, Cardoso ALC, Trabulo S, Duarte S, Pedroso de Lima MC. Cationic liposome-based systems for nucleic acid delivery: from the formulation development to therapeutic applications. In: Coelho JF, editor. Drug delivery systems: Advanced technologies potentially applicable in personalised treatments, Advances in Predictive, Preventive and Personalized Medicine. 2013; 4: 153-184.
38. Liu C. The role of microRNAs in tumors. Arch Pharm Res. 2013; 36(10): 1169-1177.
39. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21or-221arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009; 38(7): e190-e199.
40. Galardi S, Mercatelli N, Giorda E, et al. miR-221and miR-222expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007; 282(32): 23716-23724.
41. Gillies JK, Lorimer IA. Regulation of p27Kip1by miRNA 221/222in glioblastoma. Cell Cycle. 2007; 6(16): 2005-2009.
42. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008; 12(12): 2171-2176.
43. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008; 18(3): 350-359.
44. Liu C, Yu J, Yu S, et al. MicroRNA-21acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 2010; 53(1): 98-107.
45. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell. 2005; 8(3): 185-195.
46. Maitra A, Hruban RH. A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell. 2005; 8(3): 171-172.
47. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009; 4: 127-150.
48. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer. 2009; 125(6): 1407-1413.
49. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009; 219(2): 214-221.
50. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163): 682-688.
51. Gu S, Kay MA. How do miRNAs mediate translational repression? Silence. 2010; 1(1): 11.
52. Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res. 2010; 30(7): 2905-2909.
53. Hubner RA, Valle JW. Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther. 2011; 11(12): 1817-1827.
54. Sun TM, Du JZ, Yao YD, et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano. 2011; 5(2): 1483-1494.
55. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006; 17(3): 189-202.
56. Ying SY, Chang DC, Lin SL. The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol. 2008; 38(3): 257-268.
57. Eto K, Iwatsuki M, Watanabe M, et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2014; 21(1): 343-350.
58. Costa PM, Cardoso AL, Nóbrega C, et al. MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet. 2013; 22(5): 904-918.
59. Huang Y, Yang YB, Zhang XH, Yu XL, Wang ZB, Cheng XC. MicroRNA-21gene and cancer. Med Oncol. 2013; 30(1): 376.
60. Sarkar S, Dubaybo H, Ali S, et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res. 2013; 3(5): 465-477.